Home

Procyrion has announced the treatment of the first patients in the pilot trial to evaluate the performance of its novel Aortix percutaneous mechanical circulatory support (pMCS) device in patients with cardiorenal syndrome (CRS). The company began its pilot trial in Australia and recently expanded to the USA after receiving Investigational Device Exemption (IDE) approval in April from the US Food and Drug Administration (FDA).

“We are thrilled to be the first centre in the US to treat CRS patients with the Aortix device. The procedure was performed safely and easily due to the pump’s position in the aorta versus the heart, which allowed for rapid deployment of the catheter-based pump and significantly reduced the risk of stroke and damage to the heart,” stated Jennifer Cowger, medical director of the Mechanical Circulatory Support Program and Co-Director of the Cardiac Intensive Care Unit at Henry Ford Hospital in Detroit, USA. “After completing therapy, the patient showed significant improvement in the key haemodynamic parameters, shed over 10L of excess fluid, and greatly improved creatinine levels, a measure of kidney function.”

The Aortix system is a platform technology that will initially target the treatment of CRS, a multifactorial disease with cardiac, renal, and neurohormonal components contributing to its cause. The device is placed in the descending thoracic aorta via a percutaneous catheter procedure for up to seven days to simultaneously unload and rest the heart and increase perfusion of kidneys. The innovative design uses intra-aortic placement and harnesses fluid entrainment to pump blood without the need of a valve and allows for physiologically natural delivery of therapy.

“I am extremely pleased to be the first user of the Aortix system,” commented David Kaye, director of cardiology at The Alfred in Melbourne, Australia. “With CRS, low blood flow to the kidneys, as a result of underlying heart failure, causes activation of the neurohormonal system and signals the body to retain fluid, further straining the heart and exacerbating heart failure. This negative cycle causes a downward spiral in patients, leading to increased mortality and high re-admission rates. We are excited about Aortix’s potential to disrupt the harmful CRS cycle through its simultaneous cardiac unloading and enhancement of renal perfusion.”

The CRS pilot study is a prospective and multicentre trial that will enrol up to 45 patients in Australia and the USA. The study received a Category B designation and subsequent approval from Centers for Medicare & Medicaid Services (CMS), which will allow coverage of the Aortix device and routine care services during the trial.

Source CardiovascularNews

Duc Tin Clinic

Chia sẽ qua facebook bài: First patients treated with Aortix pMCS device

Chia sẽ qua google bài: First patients treated with Aortix pMCS device

Chia sẽ qua twitter bài: First patients treated with Aortix pMCS device

Chia sẽ qua MySpace bài: First patients treated with Aortix pMCS device

Chia sẽ qua LinkedIn bài: First patients treated with Aortix pMCS device

Chia sẽ qua stumbleupon bài: First patients treated with Aortix pMCS device

Chia sẽ qua icio bài: First patients treated with Aortix pMCS device

Chia sẽ qua digg bài: First patients treated with Aortix pMCS device

Chia sẽ qua yahoo bài: First patients treated with Aortix pMCS device

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.